ATE546526T1 - Hybrid-interferenz-rna - Google Patents

Hybrid-interferenz-rna

Info

Publication number
ATE546526T1
ATE546526T1 AT06743972T AT06743972T ATE546526T1 AT E546526 T1 ATE546526 T1 AT E546526T1 AT 06743972 T AT06743972 T AT 06743972T AT 06743972 T AT06743972 T AT 06743972T AT E546526 T1 ATE546526 T1 AT E546526T1
Authority
AT
Austria
Prior art keywords
interference rna
hybrid interference
hybrid
rna
molecule
Prior art date
Application number
AT06743972T
Other languages
English (en)
Inventor
Josephine Anne Milner
Michael Gait
Ming Jiang
Andrei Arzumanov
Original Assignee
Univ York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510617A external-priority patent/GB0510617D0/en
Priority claimed from GB0510612A external-priority patent/GB0510612D0/en
Priority claimed from GB0516193A external-priority patent/GB0516193D0/en
Priority claimed from GB0516191A external-priority patent/GB0516191D0/en
Application filed by Univ York filed Critical Univ York
Application granted granted Critical
Publication of ATE546526T1 publication Critical patent/ATE546526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06743972T 2005-05-25 2006-05-24 Hybrid-interferenz-rna ATE546526T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0510617A GB0510617D0 (en) 2005-05-25 2005-05-25 Hybrid interfering RNA
GB0510612A GB0510612D0 (en) 2005-05-25 2005-05-25 Polymerase chain reaction
GB0516193A GB0516193D0 (en) 2005-08-06 2005-08-06 Hybrid interfering rna
GB0516191A GB0516191D0 (en) 2005-08-06 2005-08-06 Polymerase chain reaction
PCT/GB2006/001895 WO2006125977A2 (en) 2005-05-25 2006-05-24 Hybrid interfering rna

Publications (1)

Publication Number Publication Date
ATE546526T1 true ATE546526T1 (de) 2012-03-15

Family

ID=37420934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743972T ATE546526T1 (de) 2005-05-25 2006-05-24 Hybrid-interferenz-rna

Country Status (4)

Country Link
US (2) US8067572B2 (de)
EP (1) EP1891216B1 (de)
AT (1) ATE546526T1 (de)
WO (1) WO2006125977A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304768B1 (it) * 1998-10-05 2001-03-29 Esaote Spa Lettino porta paziente o simili, e macchina, in particolare macchinaper il rilevamento d'immagini in risonanza magnetica nucleare in
EP1891216B1 (de) * 2005-05-25 2012-02-22 The University Of York Hybrid-interferenz-rna
GB0716072D0 (en) * 2007-08-17 2007-09-26 Univ York Therapy
US20120122800A1 (en) * 2008-08-08 2012-05-17 Genisphere, LLC Hatfield, Pennsylvania Long-Acting DNA Dendrimers and Methods Thereof
KR101728655B1 (ko) * 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
EP2562257A4 (de) * 2010-04-19 2014-10-01 Riken Verfahren zur stabilisierung funktioneller nukleinsäuren
US20110306653A1 (en) * 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
WO2012014945A1 (ja) * 2010-07-28 2012-02-02 国立大学法人北海道大学 アジュバント活性を有する新規核酸およびその利用
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
DK2631291T3 (da) 2010-10-22 2019-06-11 Olix Pharmaceuticals Inc Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
US20140256794A1 (en) * 2011-10-19 2014-09-11 Riken Activation of functional nucleic acid by specific modification
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
KR101567576B1 (ko) 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
US20160051693A1 (en) 2013-03-21 2016-02-25 Genisphere, Llc Cellular Delivery of DNA Intercalating Agents
EP3046583B1 (de) 2013-09-18 2019-02-13 Aura Biosciences, Inc. Virusähnliche partikelkonjugate zur behandlung von tumoren
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ，インコーポレーテッド ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
EP3416671A4 (de) 2016-02-19 2019-10-30 Genisphere, LLC Nukleinsäureträger und therapeutische verfahren zur verwendung
JP7049262B2 (ja) 2016-04-11 2022-04-06 オリックス ファーマシューティカルズ，インコーポレーテッド 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (de) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University Lange doppelsträngige rna für rna-interferenz
IL269986B2 (en) 2017-04-12 2024-06-01 Aura Biosciences Inc Targeted combination therapy
WO2020123083A1 (en) * 2018-12-12 2020-06-18 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules containing a triloop
WO2021001646A2 (en) * 2019-07-02 2021-01-07 Argonaute RNA Limited Apolipoprotein b antagonist
CN110269014B (zh) * 2019-07-23 2021-01-12 中国海洋大学 一种单环刺螠幼虫的rna干扰方法
CN115066498A (zh) * 2020-03-16 2022-09-16 阿尔戈诺特Rna有限公司 Pcsk9的拮抗剂
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
JP2024506042A (ja) * 2021-02-08 2024-02-08 ラクティゲン セラピューティクス 多価オリゴヌクレオチド薬剤およびその使用方法
WO2023041508A2 (en) * 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
JP2004535813A (ja) * 2001-07-17 2004-12-02 ミルナー，アン，ジョセフィーヌ 遺伝子発現のサイレンシング
US20030194718A1 (en) * 2002-04-15 2003-10-16 Hitachi. Ltd. Probing sequence determination system for DNA arrays
CA2505603A1 (en) * 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
JP2004261002A (ja) * 2003-01-08 2004-09-24 Tsutomu Suzuki ｓｉＲＮＡの製造方法
WO2004065415A2 (en) * 2003-01-20 2004-08-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. L-amino acid oxidase with cytotoxic activity from aplysia punctata
EP1844147A2 (de) 2005-01-18 2007-10-17 Sirna Therpeutics, Inc. Durch rna-interferenz vermittelte inhibition von retinoblastina-genexpression unter verwendung von short-interfering-nukleinsäure
EP1891216B1 (de) * 2005-05-25 2012-02-22 The University Of York Hybrid-interferenz-rna

Also Published As

Publication number Publication date
EP1891216A2 (de) 2008-02-27
US8067572B2 (en) 2011-11-29
WO2006125977A3 (en) 2007-01-25
EP1891216B1 (de) 2012-02-22
US20090012022A1 (en) 2009-01-08
WO2006125977A2 (en) 2006-11-30
US20120136040A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
ATE546526T1 (de) Hybrid-interferenz-rna
BRPI0819193A2 (pt) uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
EP1968612A4 (de) Nucleotid- und oligonucleotid-prodrugs
MX2008008261A (es) Intercambio nucleotidico dirigido mejorado con oligonucleotidos modificados por lna.
WO2010033247A3 (en) Reduced size self-delivering rnai compounds
DK1713912T3 (da) Modificerede Korte Interfererende RNA (Modificerede siRNA)
BRPI0811170A2 (pt) Oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
EP2294195A4 (de) Oligonukleotid-duplexe mit dna-ähnlichen und rna-ähnlichen nukleotiden und verwendungen dafür
EP2089517A4 (de) Polymeraseenzyme und reagenzien für erweiterte nukeinsäuresequenzierung
EP1723162A4 (de) Anti-mikrorna-oligonukleotidmoleküle
EP2064223A4 (de) Duplexoligonukleotide und verfahren zum gen-silencing durch rna-interferenz
EP1646639B8 (de) Nucleotid-phosphoramidate als antikrebs- verbindungen
WO2007021896A3 (en) Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
ATE502122T1 (de) Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
EP2071025A4 (de) Primer-set zur verstärkung des ugt1a1-gens, reagens zur verstärkung des ugt1a1-gens damit und anwendung davon
WO2006074351A3 (en) Reversible nucleotide terminators and uses thereof
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2009014612A3 (en) Modified nucleotides, methods for making and using same
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2005049832A3 (en) FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
EP2157182A3 (de) Modifizierte kurz interferierende RNA
ATE407939T1 (de) 2ß-NITROBENZYL-MODIFIZIERTE RIBONUKLEOTIDE
IL197415A0 (en) Azole nucleosides and use as inhibitors of rna and dna varial polymerases